Truist raises Glaukos stock price target to $215 on higher estimates By Investing.com
Truist Securities raised its price target for Glaukos (NYSE:GKOS) to $215 from $180 and kept a Buy rating. The stock trades at $161.66 near its 52-week high. Truist cited higher estimates, including valuation contributions from iDose and Corneal Health, and noted increased confidence after a J-code secured July 1, 2026. Glaukos reported Q2 2026 results and raised its full-year sales outlook.
How this was made
The 30-second read
Why it matters
The actionable element is the analyst’s price target increase to $215 from $180 while maintaining a Buy rating. The article does not present a new Glaukos corporate event in the text itself; it frames the PT change around higher out-year upside confidence and segment valuation multiples.
Market read
Traders may use the PT raise as a short-term sentiment input, but the lack of a new company disclosure limits decision value versus waiting for primary company updates.
What to watch
The article also notes InvestingPro fair value concerns; traders may weigh valuation risk versus the analyst’s higher out-year forecasts and J-code-related confidence.
Background
The piece is an Investing.com report on Truist Securities’ updated valuation work for Glaukos, including segment-level contributions (iDose and Corneal Health) and a reference to securing a J-code as of July 1, 2026.
Ticker impact
Truist raised Glaukos’ price target to $215 from $180 and kept a Buy rating, citing higher iDose and Corneal Health valuation assumptions.
Likely modest upside bias for GKOS into the next session(s) as traders react to the PT increase, with follow-through depending on broader biotech/medtech sentiment.
The article provides a concrete PT change and valuation drivers (iDose, Corneal Health, J-code as of July 1, 2026), but it does not introduce new Glaukos financial results or guidance beyond what is already referenced as recent news.
Market effects
Supports sentiment for ophthalmology/eye-care medtech names by reinforcing confidence in pipeline/commercial execution assumptions.
None specific beyond US small/mid-cap healthcare sentiment.
Limited; valuation methodology is company-specific.
Counterpoint
If the stock is already near its 52-week high, the incremental PT may be less impactful and could fade without new company fundamentals.
Key entities
- companyGlaukos Corporation
Subject of the analyst price target increase to $215 from $180, Buy rating maintained.
- analyst_firmTruist Securities
Raised the price target and provided valuation drivers for iDose and Corneal Health.
